Insilico Medicines拥有888M美元, 与法国Servier公司达成交易, 利用AI平台开发癌症药物。 Insilico Medicine lands up to $888M deal with French firm Servier to develop cancer drugs using its AI platform.

Insilico Medicines已经与法国的毒贩服务商达成了高达8.88亿美元的交易,以便利用其AI平台Pharma.AI发展癌症治疗, Insilico Medicine has secured an up to $888 million deal with French drugmaker Servier to develop cancer treatments using its AI platform, Pharma.AI, just days after its Hong Kong IPO. 该协议包括3 200万美元的前期和近期付款,根据里程碑增加资金。 The agreement includes $32 million in upfront and near-term payments, with additional funds based on milestones. Insilico将使用基因性人工智能设计新的药物分子,而Servier负责研发、临床测试和商业化。 Insilico will use generative AI to design new drug molecules, while Servier handles R&D, clinical testing, and commercialization. 该公司声称其AI可以将药物开发时间从4.5年缩短到12-18个月。 The company claims its AI can cut drug development time from 4.5 years to 12–18 months. 包括Eli Lilly、Fosun Pharma和Sanofi, 2025年初报告合作61次。 This deal adds to Insilico’s growing list of AI partnerships, including with Eli Lilly, Fosun Pharma, and Sanofi, with 61 collaborations reported in early 2025. 尽管Insilico公司在香港的股份略有下降,但那里的保健部门由于支持政策而增加了上市量。 Despite a slight dip in Insilico’s Hong Kong shares, the healthcare sector there saw increased listings due to supportive policies.